12:00 AM
 | 
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Tobramycin inhalation powder regulatory update

The U.K.'s NICE issued a final appraisal determination (FAD) recommending TOBI Podhaler from Novartis to treat chronic pulmonary infection caused by Pseudomonas aeruginosa in cystic fibrosis patients if nebulized tobramycin is considered an appropriate treatment. The decision is...

Read the full 168 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >